A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mohamad Adham Salkeni, Brian Ko, Brian Andrew Van Tine, Anthony Paul Conley, Elizabeth J. Davis, Melissa Amber Burgess, Julia Lee Close, Jared C. Foster, Geraldine Helen O'Sullivan Coyne, Nancy Moore, Kristin K. Fino, Katherine V. Ferry-Galow, Christina Rosenberger, Ralph E. Parchment, Elad Sharon, James H. Doroshow, Alice P. Chen
Institutions: National Institutes of Health, National Cancer Institute, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Vanderbilt University Medical Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of Florida, UF Health Cancer Center, Frederick National Laboratory for Cancer Research, Center for Cancer Research
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4379341449